Product Description
Gilead Sciences is developing Filgotinib as a treatment for Rheumatoid Arthritis (RA). (Sourced from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca-filgotinib)
Mechanisms of Action: JAK1 Inhibitor, JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Taiwan | United Kingdom
Approved Indications: None
Company: Gilead Sciences
Company Location: Western America
Company Founding Year: 1987
Additional Commercial Interests: Eisai
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Croatia, Czech Republic, Estonia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 14
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Arthritis, Rheumatoid|Axial Spondyloarthritis|Colitis, Ulcerative
Phase 2: Behcet Syndrome|IgG4-related Disease|Myositis
Phase 1: Alzheimer Disease|Arthritis, Juvenile
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06285539 |
DRIMID | P2 |
Recruiting |
Myositis|Behcet Syndrome|IgG4-related Disease |
2026-12-01 |
50% |
2024-06-28 |
Primary Endpoints|Start Date|Treatments|Trial Status |
NCT02914535 |
SELECTIONLTE | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2026-09-01 |
44% |
2023-01-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
2022-501354-10-01 |
GLPG0634-CL-336 | P3 |
Recruiting |
Axial Spondyloarthritis |
2026-05-14 |
11% |
2025-05-02 |
Treatments |
NCT03025308 |
FINCH 4 | P3 |
Completed |
Arthritis, Rheumatoid |
2025-05-16 |
57% |
2025-07-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
ACTRN12619001513101p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Alzheimer Disease |
2019-12-20 |
|||
NCT06222034 |
SCALESIA | P1 |
Recruiting |
Arthritis, Juvenile |
2026-03-01 |
50% |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Treatments |
2016-003630-25 |
2016-003630-25 | P3 |
Completed |
Arthritis, Rheumatoid |
2025-07-19 |
57% |
2025-05-30 |
Treatments |
2024-513919-27-00 |
GS-US-417-0304 | P3 |
Active, not recruiting |
Arthritis, Rheumatoid |
2025-05-28 |
2025-05-02 |
Treatments |
|
NCT05785611 |
OLINGUITO | P3 |
Active, not recruiting |
Axial Spondyloarthritis |
2024-09-04 |
11% |
2024-10-02 |
Primary Completion Date|Primary Endpoints|Treatments |
2023-505844-21-00 |
GLPG-0634-CL-131 | P1 |
Recruiting |
Arthritis, Juvenile |
2024-12-31 |
50% |
2025-05-02 |
Treatments |
NCT06865417 |
Galapeduca | P3 |
Recruiting |
Colitis, Ulcerative |
2028-06-01 |
20% |
2025-12-11 |
Primary Completion Date|Primary Endpoints|Start Date|Treatments|Trial Status |
2024-511458-32-00 |
GLPG0634-CL-331 | P3 |
Recruiting |
Colitis, Ulcerative |
2027-11-08 |
2025-05-02 |
Treatments |
|
2022-000719-30 |
2022-000719-30 | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2027-06-11 |
11% |
||
2024-516199-14-00 |
GS-US-418-3899 | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2026-12-06 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/10/2026 |
News Article |
Gilead Sciences Announces Fourth Quarter and Full Year 2025 Financial Results |
|
11/13/2025 |
News Article |
UCB's Bimzelx and AbbVie's Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth |
|
11/05/2025 |
News Article |
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update |
|
10/30/2025 |
News Article |
Gilead Sciences Announces Third Quarter 2025 Financial Results |